Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
Argus Health

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021355

« Back to Dashboard

NDA 021355 describes ANGELIQ, which is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ANGELIQ profile page.

The generic ingredient in ANGELIQ is drospirenone; estradiol. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the drospirenone; estradiol profile page.
Summary for 021355
Applicant:Bayer Hlthcare
Ingredient:drospirenone; estradiol
Formulation / Manufacturing:see details
Pharmacology for NDA: 021355
Suppliers and Packaging for NDA: 021355
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ANGELIQ drospirenone; estradiol TABLET;ORAL 021355 NDA Bayer HealthCare Pharmaceuticals Inc. 50419-482 50419-482-03 3 BLISTER PACK in 1 CARTON (50419-482-03) > 28 TABLET, FILM COATED in 1 BLISTER PACK (50419-482-01)
ANGELIQ drospirenone; estradiol TABLET;ORAL 021355 NDA Bayer HealthCare Pharmaceuticals Inc. 50419-482 50419-482-72 1 BLISTER PACK in 1 CARTON (50419-482-72) > 14 TABLET, FILM COATED in 1 BLISTER PACK (50419-482-71)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.25MG;0.5MG
Approval Date:Feb 29, 2012TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Oct 22, 2031Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.5MG;1MG
Approval Date:Sep 28, 2005TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Aug 11, 2017Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson
Farmers Insurance
US Army
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.